Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data

Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data

Astria Therapeutics, a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that preclinical data supporting STAR-0215’s profile as a potential long-acting therapy for hereditary angioedema (HAE) dosed once every three or six months has been published in the Journal of Pharmacology and Experimental Therapeutics.

Jill C. Milne, Chief Executive Officer at Astria Therapeutics, said: “We were very pleased by our publication in the Journal of Pharmacology and Experimental Therapeutics, further validating the exciting science behind STAR-0215. These results demonstrate that STAR-0215 shows high potency in vitro and in vivo and long half-life, suggesting potential for sustained, durable HAE attack suppression with subcutaneous administration.”

(Source: Astria Therapeutics)